Citations (56)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Xiaolu Bao, Weibo Zhu, Yajing Da, Linfeng Zhu, Li Qie, Yijia Yan, Li Wang, Hesheng Tang & Zhi-long Chen. (2015) Synthesis and pharmacological evaluation of a novel AT1 angiotensin II receptor antagonist with anti-hypertension and anti-tumor effects. Clinical and Experimental Hypertension 37:6, pages 490-497.
Read now
Read now
Zekeriya Arslan, Seyit Ahmet Ay, Murat Karaman, Mustafa Cakar, Turgay Celik, Sevket Balta, Muharrem Akhan, Hakan Sarlak, Erol Arslan, Seref Demirbas, Sait Demirkol, Fatih Bulucu & Kenan Saglam. (2013) An Additional LDL-Lowering Effect of Amlodipine; Not Only an Antihypertensive?. Clinical and Experimental Hypertension 35:6, pages 449-453.
Read now
Read now
S. Oparil, N. Abate, E. Chen, M. A. Creager, V. Galet, G. Jia, S. Julius, A. Lerman, P. A. Lyle, J. Pool & A. M. Tershakovec. (2008) A double-blind, randomized study evaluating losartan potassium monotherapy or in combination with hydrochlorothiazide versus placebo in obese patients with hypertension. Current Medical Research and Opinion 24:4, pages 1101-1114.
Read now
Read now
Sverre E Kjeldsen, Paulette A Lyle, Andrew M Tershakovec, Richard B Devereux, Suzanne Oparil, Björn Dahlöf, Ulf de Faire, Frej Fyhrquist, Hans Ibsen, Krister Kristianson, Ole Lederballe-Pedersen, Lars H Lindholm, Markku S Nieminen, Per Omvik & Hans Wedel. (2005) Targeting the renin–angiotensin system for the reduction of cardiovascular outcomes in hypertension: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Expert Opinion on Emerging Drugs 10:4, pages 729-745.
Read now
Read now
K. Shimamoto, N. Ura, M. Nakagawa, K. Higashiura, H. Takizawa, Y. Miyazaki, N. Nomura, A. Hirata, Y. Takagawa, H. Murakami & O. Iimura. (1996) The Mechanisms of the Improvement of Insulin Sensitivity by Angiotensin Converting Enzyme Inhibitor. Clinical and Experimental Hypertension 18:2, pages 257-266.
Read now
Read now
Articles from other publishers (51)
Mortaza Fatehi Hassanabad & Mohammad Fatehi. (2019) Current Views on Dopaminergic Drugs Affecting Glucose Homeostasis. Current Diabetes Reviews 15:2, pages 93-99.
Crossref
Crossref
Mario J.A. Saad. 2018. Endothelium and Cardiovascular Diseases. Endothelium and Cardiovascular Diseases
639
652
.
Deng-Yuan Jian, Yu-Wen Chao, Ching-Heng Ting, Seng-Wong Huang, Chao-Fu Chang, Chi-Chang Juan & Jinn-Yang Chen. (2013) Losartan ameliorates renal injury, hypertension, and adipocytokine imbalance in 5/6 nephrectomized rats. European Journal of Pharmacology 709:1-3, pages 85-92.
Crossref
Crossref
F. Xavier Pi-Sunyer, Panagiotis Kokkoris & Ignatius M.Y. Szeto. 2013. Hypertension: A Companion to Braunwald’s Heart Disease. Hypertension: A Companion to Braunwald’s Heart Disease
286
295
.
Nobuhiko Togashi, Takuto Maeda, Hideaki Yoshida, Masayuki Koyama, Marenao Tanaka, Masato Furuhashi, Kazuaki Shimamoto & Tetsuji Miura. (2011) Angiotensin II receptor activation in youth triggers persistent insulin resistance and hypertension—a legacy effect?. Hypertension Research 35:3, pages 334-340.
Crossref
Crossref
Pietro Dario Ragonesi. (2010) Effects of angiotensin II receptor blockers on insulin resistance. Hypertension Research 33:8, pages 778-778.
Crossref
Crossref
A. Storka, E. Vojtassakova, M. Mueller, S. Kapiotis, D. G. Haider, A. Jungbauer & M. Wolzt. (2008) Angiotensin inhibition stimulates PPARγ and the release of visfatin. European Journal of Clinical Investigation 38:11, pages 820-826.
Crossref
Crossref
Brian Markoff & Alison Amsterdam. (2008) Impact of obesity on hospitalized patients. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine 75:5, pages 454-459.
Crossref
Crossref
Robert M. Carey. (2008) Prevention of diabetes and left ventricular hypertrophy with AT1 receptor blockade fo hypertension. Current Hypertension Reports 10:2, pages 91-92.
Crossref
Crossref
Giuseppe SchillaciMatteo PirroElmo Mannarino. (2007) Left Ventricular Hypertrophy Reversal and Prevention of Diabetes. Hypertension 50:5, pages 851-853.
Crossref
Crossref
Marco A. de Carvalho-Filho, José Barreto C. Carvalheira, Lício Augusto Velloso & Mario José Abdalla Saad. (2007) Cross-talk das vias de sinalização de insulina e angiotensina II: implicações com a associação entre diabetes mellitus e hipertensão arterial e doença cardiovascular. Arquivos Brasileiros de Endocrinologia & Metabologia 51:2, pages 195-203.
Crossref
Crossref
F. Xavier Pi-Sunyer & Panagiotis Kokkoris. 2007. Hypertension. Hypertension
370
383
.
T A Aksnes, H M Reims, S Guptha, A Moan, I Os & S E Kjeldsen. (2006) Improved insulin sensitivity with the angiotensin II-receptor blocker losartan in patients with hypertension and other cardiovascular risk factors. Journal of Human Hypertension 20:11, pages 860-866.
Crossref
Crossref
Theodore Kurtz. 2006. Angiotensin II Receptor Antagonists. Angiotensin II Receptor Antagonists
85
98
.
Mark E Cooper, Chris Tikellis & Merlin C Thomas. (2006) Preventing diabetes in patients with hypertension: one more reason to block the renin–angiotensin system. Journal of Hypertension 24:Suppl 1, pages S57-S63.
Crossref
Crossref
Licio A. Velloso, Franco Folli, Lucia Perego & Mario J. A. Saad. (2006) The multi-faceted cross-talk between the insulin and angiotensin II signaling systems. Diabetes/Metabolism Research and Reviews 22:2, pages 98-107.
Crossref
Crossref
Salvatore Di Somma & Alberto Sentimentale. (2006) New Onset of Type 2 Diabetes Mellitus during Antihypertensive Therapy. High Blood Pressure & Cardiovascular Prevention 13:1, pages 29-36.
Crossref
Crossref
AJ Scheen. (2004) Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Diabetes & Metabolism 30:6, pages 498-505.
Crossref
Crossref
S. S. Daskalopoulou, D. P. Mikhailidis & M. Elisaf. (2016) Prevention and Treatment of the Metabolic Syndrome. Angiology 55:6, pages 589-612.
Crossref
Crossref
Andr?? J Scheen. (2004) Prevention of Type 2 Diabetes Mellitus Through Inhibition of the Renin-Angiotensin System. Drugs 64:22, pages 2537-2565.
Crossref
Crossref
J. C. Balt & M. Pfaffendorf. 2004. Angiotensin Vol. I. Angiotensin Vol. I
351
372
.
A. Nap, J. C. Balt, M. J. Mathy & P. A. van Zwieten. (2003) AT1-receptor blockade and sympathetic neurotransmission in cardiovascular disease. Autonomic and Autacoid Pharmacology 23:5-6, pages 285-296.
Crossref
Crossref
Raymond R. Townsend. (2003) Angiotensin and insulin resistance: Conspiracy theory. Current Hypertension Reports 5:2, pages 110-116.
Crossref
Crossref
Elena Bernobich, Luisa de Angelis, Carlos Lerin & Giuseppe Bellini. (2002) The Role of the Angiotensin System in Cardiac Glucose Homeostasis. Drugs 62:9, pages 1295-1314.
Crossref
Crossref
S. Nielsen, K. Y. Hove, J. Dollerup, P. L. Poulsen, J. S. Christiansen, O. Schmitz & C. E. Mogensen. (2001) Losartan modifies glomerular hyperfiltration and insulin sensitivity in type 1 diabetes. Diabetes, Obesity and Metabolism 3:6, pages 463-471.
Crossref
Crossref
Chris M Terpening. (2016) Mediators of Chronic Heart Failure: How Drugs Work. Annals of Pharmacotherapy 35:9, pages 1066-1074.
Crossref
Crossref
Michael J. Katovich, Phyllis Y. Reaves, Sharon C. Francis, Alok S. Pachori, Hong-Wei Wang & Mohan K. Raizada. (2001) Gene therapy attenuates the elevated blood pressure and glucose intolerance in an insulin-resistant model of hypertension. Journal of Hypertension 19:9, pages 1553-1558.
Crossref
Crossref
M HanefeldC Abletshauser. (2016) Effect of the Angiotensin II Receptor Antagonist Valsartan on Lipid Profile and Glucose Metabolism in Patients with Hypertension. Journal of International Medical Research 29:4, pages 270-279.
Crossref
Crossref
Arya M. Sharma, Tobias Pischon, Stefan Engeli & Juergen Scholze. (2001) Choice of drug treatment for obesity-related hypertension: where is the evidence?. Journal of Hypertension 19:4, pages 667-674.
Crossref
Crossref
K. Higashiura, N. Ura, T. Takada, Y. Li, T. Torii, N. Togashi, M. Takada, H. Takizawa & K. Shimamoto. (2000) The effects of an angiotensin-converting enzyme inhibitor and an angiotensin II receptor antagonist on insulin resistance in fructose-fed rats. American Journal of Hypertension 13:3, pages 290-297.
Crossref
Crossref
M. Frossard, Ch. Joukhadar, G. Steffen, R. Schmid, H.G. Eichler & M. Müller. (2000) Paracrine effects of angiotensin-converting-enzyme- and angiotensin-II-receptor-inhibition on transcapillary glucose transport in humans. Life Sciences 66:10, pages PL147-PL154.
Crossref
Crossref
Nobuyuki Ura, Katsuhiro Higashiura & Kazuaki Shimamoto. (1999) The mechanisms of insulin sensitivity improving effects of angiotensin converting enzyme inhibitor. Immunopharmacology 44:1-2, pages 153-159.
Crossref
Crossref
Nasser Mikhail, Michael S. Golub & Michael L. Tuck. (1999) Obesity and hypertension. Progress in Cardiovascular Diseases 42:1, pages 39-58.
Crossref
Crossref
J. Schrader & S. Lüders. 1999. Angiotensin II AT1-Rezeptorantagonisten. Angiotensin II AT1-Rezeptorantagonisten
145
178
.
Peter Trenkwalder. 1999. AT1-Rezeptorblockade. AT1-Rezeptorblockade
235
243
.
András Mogyorósi & Sándor Sonkodi. (1999) AT1 receptor antagonists: a challenge for ACE inhibitors in diabetic nephropathy. Diabetes/Metabolism Research and Reviews 15:1, pages 55-58.
Crossref
Crossref
AC Leary & TM MacDonald. (1998) ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKADE: A NEW DEVELOPMENT IN CARDIOVASCULAR PHARMACOLOGY. International Journal of Clinical Practice 52:7, pages 475-481.
Crossref
Crossref
M. Lerch, A. U. Teuscher, P. Beissner, M. Schneider, S. G. Shaw & P. Weidmann. (1998) Effects of Angiotensin II-Receptor Blockade with Losartan on Insulin Sensitivity, Lipid Profile, and Endothelin in Normotensive Offspring of Hypertensive Parents. Journal of Cardiovascular Pharmacology 31:4, pages 576-580.
Crossref
Crossref
Roberto Giovannetti, Claudia Del Corso, Francesco Galeone, Franco Giuntoli & Paolo Saba. (1997) Efficacy and safety of losartan in hypertensive patients with side effects induced by other antihypertensive agents. Current Therapeutic Research 58:11, pages 851-858.
Crossref
Crossref
Hitomi Yokoyama, Shinya Minatoguchi, Masatoshi Koshiji, Yoshihiro Uno, Masao Kakami, Chisato Nagata, Hiroyasu Ito & Hisayoshi Fujiwara. (1997) LOSARTAN AND CAPTOPRIL FOLLOW DIFFERENT MECHANISMS TO DECREASE PRESSOR RESPONSES IN THE PITHED RAT. Clinical and Experimental Pharmacology and Physiology 24:9-10, pages 697-705.
Crossref
Crossref
Talma RosenthalYael ErlichEliezer RosenmannAharon Cohen. (1997) Effects of Enalapril, Losartan, and Verapamil on Blood Pressure and Glucose Metabolism in the Cohen-Rosenthal Diabetic Hypertensive Rat. Hypertension 29:6, pages 1260-1264.
Crossref
Crossref
Larry Chow, Marc De Gasparo & Nigel Levens. (1997) Blockade of angiotensin converting enzyme but not of angiotensin AT1 receptors improves glucose tolerance. European Journal of Pharmacology 319:1, pages 77-83.
Crossref
Crossref
J. Schrader & S. Lüders. 1997. Angiotensin II AT1-Rezeptorantagonisten. Angiotensin II AT1-Rezeptorantagonisten
141
168
.
Markku LaaksoLeena KarjalainenPäivi Lempiäinen-Kuosa. (1996) Effects of Losartan on Insulin Sensitivity in Hypertensive Subjects. Hypertension 28:3, pages 392-396.
Crossref
Crossref
Ingebjørg SeljeflotAndreas MoanSverre KjeldsenEndre SandvikHarald Arnesen. (1996) Effect of Angiotensin II Receptor Blockade on Fibrinolysis During Acute Hyperinsulinemia in Patients With Essential Hypertension. Hypertension 27:6, pages 1299-1304.
Crossref
Crossref
Albert A. Carr & L. Michael Prisant. (2013) Losartan: First of a New Class of Angiotensin Antagonists for the Management of Hypertension. The Journal of Clinical Pharmacology 36:1, pages 3-12.
Crossref
Crossref
C.I Johnston. (1995) Angiotensin receptor antagonists: focus on losartan. The Lancet 346:8987, pages 1403-1407.
Crossref
Crossref
Larry Chow, Marc De Gasparo & Nigel Levens. (1995) Improved glucose metabolism following blockade of angiotensin converting enzyme but not angiotensin AT1 receptors. European Journal of Pharmacology 282:1-3, pages 77-86.
Crossref
Crossref
I. Seljeflot, H. Arnesen, R. Støen & T. Lyberg. (1995) Effects of insulin and some vasoconstrictors on the synthesis and release of t-PA and PAI-1 from cultured human umbilical vein endothelial cells. Fibrinolysis 9:4, pages 253-258.
Crossref
Crossref
Harold D. Itskovitz. (1995) Antihypertensive therapy targeted to the needs of the patient: Focus on the renin-angiotensin system; Older and Newer Agents. Clinical Cardiology 18:S3, pages 23-28.
Crossref
Crossref
Murray Epstein. (1995) Evolving concepts in the management of hypertension. Clinical Cardiology 18:S3, pages 3-11.
Crossref
Crossref